Effect of Arg16Gly polymorphism status on proportion of salmeterol treated patients (BTS step 3 and above) with asthma exacerbations
| Treatment | Genotype | Total exacerbations | Total | OR(p values) | |
|---|---|---|---|---|---|
| Yes | No | ||||
| *p values were calculated by binary logistic regression analysis corrected for age, sex, and exposure to tobacco smoke, using a co-dominant model. Odds ratios are per genotypic step. | |||||
| Not on salmeterol | GlyGly | 48 (33%) | 97 | 145 | 1.26(p = 0.149)* |
| ArgGly | 61 (35%) | 117 | 178 | ||
| ArgArg | 25 (41%) | 34 | 59 | ||
| Total | 132 | 248 | 382 | ||
| On regular salmeterol | GlyGly | 26 (41%) | 37 | 63 | 1.79(p = 0.020)* |
| ArgGly | 39 (51%) | 37 | 76 | ||
| ArgArg | 16 (64%) | 9 | 25 | ||
| Total | 81 | 83 | 164 | ||